科笛集团：CU-40102（外用非那雄胺喷雾剂）获国家药监局上市批准

Core Insights - Codex Group announced that CU-40102 (topical finasteride spray) has received approval from the National Medical Products Administration for the treatment of androgenetic alopecia, marking it as the first and only approved topical finasteride for this condition globally and in China [1] Company Summary - CU-40102 is based on results from a Phase III confirmatory clinical trial, demonstrating its effectiveness in treating androgenetic alopecia, with good local tolerability reported by participants [1] - This approval will enhance Codex Group's commercialization strategy in the dermatology treatment and care sector [1]